Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Chiesi Farmaceutici and Samay Announce Collaboration to Advance Early Detection of Small Airway Disease

PARMA, ITALY AND MOUNTAIN VIEW, CA, NY / ACCESS Newswire / October 9, 2025 / Chiesi Farmaceutici S.p.A. ("Chiesi"), a global research-focused biopharmaceutical group with a strong heritage in respiratory care, and Samay, the 2024 global winner of MedTech Innovator, today announced their collaboration aimed at developing novel algorithms to detect small airway disease (SAD), an early pathological feature of chronic obstructive pulmonary disease (COPD).

SAD can manifest up to several years (2-5) before abnormalities are detectable by standard spirometry, making its early identification a critical step in enabling earlier diagnosis, intervention, and treatment.

The collaboration combines Chiesi's deep expertise in respiratory therapies with Samay's proprietary technology Sylvee, a wearable chest sensor powered by acoustic resonance and AI-driven analytics, in order to bring impactful advantages to patients through both better monitoring and stronger evaluation of treatments efficacy.

Under the agreement, the partners will conduct an initial pilot study expected to deliver results by April 2026. Pending positive outcomes, the initiative has been designed to broaden the diagnostic landscape for COPD and other respiratory diseases.

"At Chiesi, our mission is to improve the quality of life for patients living with respiratory conditions. Leveraging Samay's innovative wearable technology, we aim to address one pressing challenge in respiratory medicine: the early detection of small airway disease," said Michelle Soriano, Executive Vice President Air Franchise, Chiesi Group.

"Partnering with Chiesi brings us closer to our vision of transforming respiratory diagnostics. Early detection of SAD not only creates significant market opportunities but, more importantly, gives patients and clinicians a new tool to intervene before COPD progresses irreversibly. We are proud to collaborate with a global leader in respiratory care to advance this important mission," said Dr. Maria Artunduaga, Founder & CEO, Samay.

Images available here

About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment.

By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit www.chiesi.com.

About Samay

Samay develops AI-powered wearable solutions for the diagnosis and management of chronic respiratory diseases. Headquartered in Mountain View, Calif., with operations in Colombia, the company has secured more than $5.2 million in funding, including federal grants and venture investments. The 2024 global winner of MedTech Innovator and 2025 Success Story at the Respiratory Innovation Summit, Samay has established partnerships with top U.S. medical institutions. For more information, visit www.samayhealth.com.

About Technology

Samay's Sylvee has been validated in more than 400 subjects, including patients with COPD and asthma. By eliminating the need for costly specialized staff to interpret results, Sylvee reduces barriers to widespread diagnostic adoption, particularly in primary care and low-resource settings. If successful, the collaboration could expand access to early diagnostics globally while strengthening Samay's regulatory pathway in the U.S. and Latin America, including anticipated FDA submissions and a market entry in Colombia by 2027.

References include:

Press info

For Chiesi:
mediarelations@chiesi.com

For Samay:

Erica Zeidenberg
Hot Tomato Marketing
erica@hottomato.net
925.518.8159

SOURCE: Samay



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.